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OBJECTIVES We sought to assess whether aortic valve replacement (AVR) among patients with severe
aortic stenosis (AS), severe left ventricular (LV) dysfunction and a low transvalvular gradient
(TVG) is associated with improved survival.
BACKGROUND The optimal management of patients with severe AS with severe LV dysfunction and a low
TVG remains controversial.
METHODS Between 1990 and 1998, we evaluated 68 patients who underwent AVR at our institution
(AVR group) and 89 patients who did not undergo AVR (control group), with an aortic valve
area 0.75 cm2, LV ejection fraction 35% and mean gradient 30 mm Hg. Using
propensity analysis, survival was compared between a cohort of 39 patients in the AVR group
and 56 patients in the control group.
RESULTS Despite well-matched baseline characteristics among propensity-matched patients, the one-
and four-year survival rates were markedly improved in patients in the AVR group (82% and
78%), as compared with patients in the control group (41% and 15%; p  0.0001). By
multivariable analysis, the main predictor of improved survival was AVR (adjusted risk ratio
0.19, 95% confidence interval 0.09 to 0.39; p  0.0001). The only other predictors of
mortality were age and the serum creatinine level.
CONCLUSIONS Among select patients with severe AS, severe LV dysfunction and a low TVG, AVR was
associated with significantly improved survival. (J Am Coll Cardiol 2002;39:1356–63)
© 2002 by the American College of Cardiology Foundation
Symptomatic severe valvular aortic stenosis (AS), with a
high transvalvular gradient (TVG) and valve area
0.75 cm2, is associated with a high mortality for medically
treated patients (1–3), although survival is improved after
aortic valve replacement (AVR) (3). When left ventricular
(LV) dysfunction develops due to excessive afterload and
wall stress and the TVG remains high, the results of AVR
remain acceptable (4–6).
See page 1364
For patients with severe AS in the presence of severe LV
dysfunction and a mean TVG 30 mm Hg, the benefits of
AVR remain controversial. Only a small number of select
patients with these characteristics, often from older series,
have had their outcome reported after AVR, with conflict-
ing results (5,7–12) and with limited power to determine
the predictors of survival. The largest series of 52 surgical
patients reported by Connolly et al. (12) showed a marked
improvement in functional class among 30-day survivors,
although the perioperative mortality rate was 21%. Further-
more, no studies have assessed survival in the absence of
AVR among this high-risk cohort.
Therefore, we reviewed our institution’s experience to test
the hypothesis that among patients with severe AS with
severe LV dysfunction and a low TVG, AVR results in
improved survival.
METHODS
Patient selection. From the echocardiographic and surgi-
cal databases of our institution, we identified all patients
from January 1, 1990 to November 20, 1998 who had an
aortic valve area (AVA) 0.75 cm2, LV ejection fraction
(LVEF)35% and mean TVG30 mm Hg. Patients were
excluded if they had more than moderate (2) aortic
regurgitation by echocardiography, had undergone valve
replacement or repair previously or required any valve
replacement in addition to AVR during the operation.
Patients who underwent concomitant coronary artery bypass
graft surgery (CABG) or mitral or tricuspid valve repair
were eligible.
Sixty-eight consecutive patients received AVR (AVR
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group), and 95 consecutive patients did not receive AVR
(control group). Of these 95 patients, 5 were excluded
because of the presence of life-threatening noncardiac con-
ditions, and 1 was excluded because of heart transplantation,
resulting in 89 patients in the control group.
Data collection. Preoperative clinical data, echocardio-
graphic results, cardiac catheterization hemodynamic data,
native coronary anatomy (if catheterization was performed)
and operative data were obtained by reviewing the medical
records and data bases. Survival from the date of echocar-
diography was obtained by using the Social Security Death
Index of all patients (13,14) and was validated at clinical
follow-up in 74% of patients in the AVR and control
groups. Follow-up was for a minimum of six months (range
0.5 to 7.5 years). Late postoperative New York Heart
Association (NYHA) and Canadian Cardiovascular Society
(CCS) functional classes were also assessed in 44 of 46
long-term survivors in the AVR group, by telephone inter-
view with the patient or physician, mail questionnaire or
review of the medical records.
Echocardiography. Comprehensive two-dimensional
echocardiography and preoperative Doppler transthoracic
echocardiography were performed in all patients. Left ven-
tricular ejection fraction and right ventricular function were
determined by visual estimation. This method of assessing
LVEF has been widely employed (6,12,15), and its validity
has been confirmed in several studies (16–19), including
one that suggests superiority of visual estimation of LVEF
over quantitative methods (18). Moreover, when we as-
sessed whether the visually estimated LVEF among the 89
patients in the control group, stratified by LVEF 20% or
20%, predicted survival, the survival curves diverged
immediately and were considerably worse (p 0.05) among
patients with LVEF 20%, further supporting the validity
of this method.
In addition, as an internal validation, among the 157
patients in the AVR and control groups, we quantified, by
the volumetric method (20), LVEF in 42 (27%) randomly
selected echocardiographic studies. Among these patients,
LVEF was visually estimated at 23  7% and calculated to
be 24  9% (r  0.60, p  0.001). Furthermore, in those
studies in which LVEF was calculated, only five patients
had LVEF 35% (with peak and mean gradients of 42 and
25 mm Hg), and of these patients, none had LVEF 45%.
Regional LV wall motion abnormalities were categorized
according to a standard 16-segment model (20). Aortic
valve hemodynamic data were assessed using standard
methods, and the AVA was calculated by the continuity
equation (21). Mitral and aortic regurgitation was semi-
quantitated from 0 (none) to 4 (severe) (22,23). A relative
wall thickness ratio (24) and AVA index (AVA/body
surface area) were calculated.
Cardiac catheterization. Coronary artery disease (CAD)
was defined as 50% lumen diameter narrowing of the left
main or major epicardial vessels. Multivessel CAD was
defined as either left main or two or three major epicardial
vessel disease. Aortic valve area was calculated from the
Gorlin equation (25). Cardiac output was determined by
either the Fick or thermodilution method.
Surgical procedures. The type and size of the aortic
prosthesis used in AVR, concomitant CABG or mitral or
tricuspid valve repair, as well as the aortic cross-clamp time
and cardiopulmonary bypass time, were recorded in the
AVR group. In-hospital deaths were defined as deaths
before hospital discharge.
Development of AVR propensity scores. Using propen-
sity analysis (26), a logistic regression model (27) was
created, where AVR was the dependent variable, and 20
observed and plausible correlates of AVR acted as indepen-
dent variables, including LVEF, right ventricular systolic
function, LV end-diastolic dimension and wall thickness,
severity of mitral regurgitation, mean aortic TVG and AVA
at echocardiography, age, gender, race, NYHA and CCS
functional classes, syncope, diabetes mellitus, hypertension,
previous myocardial infarction or CABG, peripheral vascu-
lar disease, chronic airway obstruction and serum creatinine.
The most important correlates of receiving AVR were
younger age, higher mean TVG and male gender. A
nonparsimonious propensity score for AVR was generated
among the 157 patients who had severe AS with severe LV
dysfunction and a low TVG. The area under the receiver
operating characteristics curve was 0.86, indicating good dis-
crimination between patients who received and did not receive
AVR. After dividing the study group into quintiles, based on
propensity scores, patients in propensity quintiles 2 to 4, where
the probability of AVR ranged from 11% to 80%, had
reasonable matching of propensity scores, variances of propen-
sity scores and baseline characteristics. Further analyses were
confined to these propensity-matched patients; 39 patients in
the AVR group and 56 patients in the control group. Among
patients in quintile 1, who were least likely to receive AVR,
there were 31 patients in the control group and 0 patients in
the AVR group. Among patients in quintile 5, who were most
likely to receive AVR, there were 29 patients in the AVR
group and 2 patients in the control group.
Statistical analysis. Group data were expressed as the
mean value  SD for continuous variables or as percent
frequencies for categorical variables. Clinical, echocardio-
Abbreviations and Acronyms
AS  aortic stenosis
AVR  aortic valve replacement
AVA  aortic valve area
CABG  coronary artery bypass graft surgery
CAD  coronary artery disease
CCS  Canadian Cardiovascular Society
CI  confidence interval
LV  left ventricular
LVEF  left ventricular ejection fraction
NYHA  New York Heart Association
RR  risk ratio
TVG  transvalvular gradient
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graphic, cardiac catheterization and surgical data were
compared between patients by using the t test, Wilcoxon
rank-sum test or chi-square test, as appropriate. The Mc-
Nemar test statistic was determined to compare preopera-
tive and postoperative functional classes. Propensity analysis
(26) was used to calculate a propensity score for each
patient; this score represented the probability of receiving
AVR. Survival was analyzed by constructing Kaplan-Meier
curves (28) among patients who did or did not receive AVR,
and was expressed as the mean value  SEM. The Cox
proportional hazards model (29) was used to assess the
association between AVR and time to death, with the pro-
portional hazards assumption confirmed by testing the
time-dependent covariates. The relationship between pre-
operative variables and postoperative LVEF was assessed by
simple and multiple linear regression analyses. All statistical
analyses were performed using the SAS system (version 8.1,
SAS Inc., Cary, North Carolina), except for the relationship
between preoperative variables and postoperative LVEF
(SPSS version 10.0, SPSS Inc., Chicago, Illinois).
RESULTS
Clinical characteristics. Among patients in the AVR and
control groups, 22 (32%) and 74 (83%) deaths occurred over
2.7  2.3 years and 1.0  1.3 years of follow-up, respec-
tively. The baseline characteristics of the total study group
are summarized in Tables 1 and 2, and the survival curves of
the total study group are shown in Figure 1. The baseline
characteristics of the propensity-matched patients are
shown in Table 3.
Among patients in the AVR group, 24 patients (35%)
received a prosthesis that was 22 mm in size, whereas 44
patients (65%) received a prosthesis 22 mm. Among
patients in the AVR group, a sub-group of 24 (35%) patients
received a prosthesis that was22 mm while a sub-group of 44
(65%) patients received a prosthesis 22 mm. There was no
difference in the percentage that received bioprostheses in
either sub-group (79% vs. 77%, respectively; pNS). All four
patients who died perioperatively received a 21-mm prosthesis,
three of which were bioprostheses.
Hospital mortality among propensity-matched pa-
tients. Among the 39 patients in the AVR group, there
were three in-hospital deaths (8%) that occurred on post-
operative days 2, 44 and 56. Among the 56 patients in the
control group, there were eight in-hospital deaths (14%).
Medium-term survival among propensity-matched
patients. Kaplan-Meier analysis of survival of all
propensity-matched patients is shown in Figure 2. The
median follow-up among in-hospital survivors in the AVR
group was 2.13 years (25th to 75th percentile: 0.83 to 4.78
years). In addition to the three perioperative deaths, there
were 11 deaths at late follow-up. One- and four-year
survival rates were 82  6% and 78  7%, respectively. The
median follow-up period among in-hospital survivors in the
control group was 0.75 years (25th to 75th percentile: 0.16
to 1.66 years). In addition to the eight in-hospital deaths,
there were 39 deaths at late follow-up. One- and four-year
survival rates were 41  7% and 15  5%, respectively.
Multivariable predictors of mortality among propensity-
matched patients. Among the 95 propensity-matched
subjects in quintiles 2 to 4, there were 61 deaths. A series of
Cox regression models relating receiving or not receiving
Table 1. Baseline Characteristics of Total Study Group: Clinical and Echocardiography Data
AVR Group
(n  68)
Control Group
(n  89)
Clinical data
Age, in years (range) 70  9 (44–86) 77  8 (51–93)*
Male/female (%) 84/16 64/36*
Body surface area (m2) 1.92  0.2 1.81  0.2*
Syncope 10 (15%) 18 (20%)
Cardiogenic shock 2 (3%) 4 (4%)
NYHA functional class III/IV 44 (65%) 71 (80%)*
Previous MI 35 (51%) 34 (38%)
Previous CABG 21 (31%) 31 (35%)
Previous percutaneous aortic valvuloplasty 4 (6%) 2 (2%)
Diabetes mellitus 16 (24%) 32 (36%)
Systemic hypertension 41 (60%) 52 (58%)
Creatinine level (mg/dl) 1.5  1.0 2.0  1.9*
Echocardiographic data
Aortic valve area (cm2) 0.62  0.11 0.61  0.09
Mean TVG in mm Hg (range) 25  4 (11–30) 22  5 (8–30)
Peak TVG (mm Hg) 43  8 39  9
Moderate to severe mitral regurgitation 30 (44%) 58 (65%)*
Pulmonary artery systolic pressure (mm Hg) 47  13 53  14*
LV ejection fraction (%) 22  6 23  8
Moderate to severe right ventricular dysfunction 26 (38%) 32 (36%)
*p  0.05 for AVR versus control group. Data are presented as the mean value  SD or number (%) of patients.
AVR  aortic valve replacement; CABG  coronary artery bypass graft surgery; LV  left ventricular; MI  myocardial
infarction; NYHA  New York Heart Association; TVG  transvalvular gradient.
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AVR to the risk of death, adjusted for propensity score and
six other covariates (i.e., age, serum creatinine level, LVEF,
gender, AVA, body surface area), found that receiving AVR
remained a strong and independent predictor of survival
(adjusted risk ratio (RR) 0.19, 95% confidence interval [CI]
0.09 to 0.39, p  0.0001), with an 81% decrease in the risk
of death. Other variables that predicted mortality were
elevated serum creatinine (1.5 mg/dl; RR 1.5, 95% CI 1.2
to 1.9, p  0.0005) and increased age per one-year incre-
ment (RR 1.05, 95% CI 1.02 to 1.07, p  0.002).
When the reason for not receiving AVR was determined
as being due to patient refusal, the decision of the physician
assessing the patient or significant comorbidities, there were
no differences in the survival of each of these patients.
Similarly, among those patients in the control group who
received or did not receive cardiac catheterization, survival
was equally poor. As shown in Table 4, for patients who had
AVR, there was no preoperative mean TVG below which
survival deteriorated (either perioperative or late deaths). No
interactions between receiving AVR, older age, renal dys-
function and LVEF were noted for the prediction of
mortality.
Table 2. Baseline Characteristics of Total Study Group: Cardiac Catheterization and
Surgical Data
AVR Group
(n  68)
Control Group
(n  89)
Cardiac catheterization data
Multivessel coronary artery disease 45 (66) 29 (66)
(n  68) (n  44)
Aortic valve area 0.81  0.23 0.86  0.35
(n  40) (n  26)
Peak to peak TVG (mm Hg) 35  16 29  16
(n  45) (n  30)
Cardiac index (l/min per m2) 2.2  0.5 2.1  0.6
(n  44) (n  35)
Surgical data
Emergent surgery 2 (3%) NA
Concomitant CABG 41 (60%) NA
Concomitant mitral valve repair 9 (13%) NA
Mean aortic prosthesis size in mm (range) 22.5  1.7 (19–27) NA
Bioprosthesis 53 (78%) NA
CE pericardial/homograft 51/2 NA
Mechanical valve 15 (22%) NA
Aortic cross-clamp time (min) 87  32 NA
Cardiopulmonary bypass time (min) 124  41 NA
p  0.10 for all cardiac catheterization indexes: AVR versus control groups. Data are presented as the mean value  SD or
number (%) of patients.
AVR  aortic valve replacement; CABG  coronary artery bypass graft surgery; CE pericardial  Carpentier-Edwards
bovine pericardial tissue valve; NA  not applicable; TVG  transvalvular gradient.
Figure 1. Survival by Kaplan-Meier analysis among all patients in the aortic valve replacement (AVR) and control (No AVR) groups (p  0.0001). The
number of patients at risk during follow-up is shown on the x axis. Echo  echocardiography.
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Change in functional class in patients who had
AVR. Among 44 of 46 long-term survivors, the incidence
of NYHA functional class III or IV symptoms decreased
from 68% to 18% (Fig. 3), whereas CCS class III or IV
symptoms decreased from 23% to 2% at follow-up (p 
0.001).
Doppler hemodynamic data and LVEF in patients who
had AVR. The LVEF was assessed by echocardiography at
a mean interval of 21 months after AVR in 53 (83%) of 64
in-hospital survivors. The overall change in LVEF was from
21 7% to 30 12% (p 0.001). In the patients in whom
LVEF was assessed after AVR, 35 (66%) of 53 showed an
Table 3. Baseline Characteristics of Propensity-Matched Patients in Quintiles 2 to 4
AVR Group
(n  39)
Control Group
(n  56) p Value
Clinical data
Age, in years (range) 73  9 (44–86) 75  6 (58–90) 0.66
Male/female (%) 77/23 73/27 0.68
Body surface area (m2) 1.89  0.22 1.84  0.21 0.51
NYHA functional class III/IV 29 (74%) 40 (71%) 0.75
CCS class III/IV 12 (31%) 14 (25%) 0.54
Syncope 5 (13%) 8 (14%) 0.84
Previous MI 20 (51%) 23 (41%) 0.33
Previous CABG 14 (36%) 20 (36%) 0.99
Diabetes mellitus 15 (38%) 19 (34%) 0.65
Systemic hypertension 22 (56%) 33 (59%) 0.81
Creatinine level (mg/dl) 1.7  1.3 1.7  1.3 0.44
Multivessel CAD on angiogram 27 (69%) 18 (62%) 0.5
(n  39) (n  29)
Echocardiographic data
Aortic valve area (cm2) 0.60  0.12 0.60  0.09 0.66
Mean TVG in mm Hg (range) 24  5 (11–30) 24  4 (14–30) 0.60
Peak TVG (mm Hg) 41  8 41  8 0.83
Moderate to severe mitral regurgitation 23 (59%) 33 (59%) 1.0
Pulmonary artery systolic pressure (mm Hg) 47  13 52  13 0.04
(n  25) (n  34)
LV ejection fraction (%) 22  6 23  8 0.36
LV end-diastolic diameter (cm) 6.2  0.6 6.1  0.7 0.08
LV end-systolic diameter (cm) 5.0  0.8 5.0  0.7 0.40
Moderate to severe right ventricular dysfunction 22 (56%) 35 (63%) 0.55
Data are presented as the mean value  SD or number (%) of patients.
AVR  aortic valve replacement; CABG  coronary artery bypass graft surgery; CAD  coronary artery disease; CCS 
Canadian Cardiovascular Society; LV  left ventricular; MI  myocardial infarction; NYHA  New York Heart Association;
TVG  transvalvular gradient.
Figure 2. Survival by Kaplan-Meier analysis among all propensity-matched patients in the aortic valve replacement (AVR) and control (No AVR) groups
(p  0.0001). The number of patients at risk during follow-up is shown on the x axis. Echo  echocardiography.
1360 Pereira et al. JACC Vol. 39, No. 8, 2002
Aortic Stenosis With Low TVG and LV Dysfunction April 17, 2002:1356–63
increase of 15  9% in LVEF. After multiple linear
regression analysis, the presence of syncope (p  0.02) and
the absence of hypertension remained the only independent
predictors of a postoperative increase in LVEF (p  0.04).
Postoperative TVGs after AVR were recorded among 52
(81%) of 64 in-hospital survivors. The mean TVG de-
creased from 25  4 mm Hg to 13  5 mm Hg, and the
peak TVG decreased from 42  7 mm Hg to 23  9 mm
Hg (p  0.001). Among the 42 patients with a bioprosthe-
sis, the postoperative mean TVG was less than that of
the 10 patients with a mechanical valve (12  4 mm Hg vs.
17  8 mm Hg, p  0.007).
DISCUSSION
We report the first study comparing survival among patients
with well-defined, low TVGs with severe AS and severe LV
systolic dysfunction who did and did not receive AVR.
Despite similar propensity scores and baseline characteris-
tics among patients in the AVR and control groups, patients
who did not have AVR were at increased risk of death over
the short to medium term.
Previous studies. The benefit of AVR for severe AS,
clinical heart failure and LV dysfunction was first demon-
strated in the 1970s in a series of 19 patients (4). The benefit
of AVR, despite the presence of LV dysfunction, was
confirmed in a larger series of 154 patients with an elevated
TVG who underwent AVR (6). Few series have assessed the
outcome exclusively among patients with severe AS with a
low mean TVG (9,12) and with severe LV dysfunction (12).
Connolly et al. presented the results of 52 patients who
underwent AVR from 1985 to 1995, with an AVA of 0.7
0.2 cm2 (range 0.3 to 1.2 cm2), mean aortic valve gradient of
23 4 mm Hg and LVEF of 26 8%. Similar to an earlier
study that consisted of 18 patients exclusively in NYHA
functional class III or IV with low-gradient, severe AS (9),
there was considerable perioperative mortality (21%). The
overall three-year survival rate was 62%, but in the absence
of CAD, there was a much better outcome, with three- and
five-year survival rates of 71%. Multivariable analysis iden-
tified a small prosthesis size as the only predictor of
perioperative mortality. In both these studies (9,12), there
was an improvement in functional class.
In comparison, there have been no studies that have
specifically assessed survival in patients with severe AS with
severe LV dysfunction and a low TVG who did not receive
AVR. In a nonrandomized study of symptomatic patients with
severe AS with high gradients and preserved LVEF, survival at
three years was poor (21%) in those patients who refused AVR,
as compared with 87% in those who underwent AVR (3).
Survival benefit among propensity-matched patients who
had AVR. Because the decision to perform AVR was not
based on a randomized assignment, we used propensity
analysis (26) to account for presumed confounding and
selection biases. This method, including its advantages and
limitations, has been discussed in detail elsewhere (30,31)
and has already been used to assess a number of cardiovas-
cular interventions (32,33). Among the 95 propensity-
matched patients, survival among patients who did not
receive AVR remained poor. In contrast, receiving AVR
was the strongest predictor of survival, decreasing all-cause
mortality by 81%.
Table 4. Perioperative and Late Deaths Related to the MTVG Among Patients Who Had AVR
Replacement
AVR Group
(n  68)
Perioperative
Deaths
Late
Deaths
Total
Deaths
Preoperative MTVG
(mm Hg)
20 9 0 3 (33%) 3 (33%)
20–25 18 1 (5.5%) 3 (16.5%) 4 (22%)
25–30 41 3 (7%) 12 (29%) 15 (36%)
Preoperative MTVG
(mm Hg)
20 8* 0 3 (38%) 3 (38%)
20–25 12* 1 (8%) 3 (25%) 4 (25%)
25–30 19* 2 (11%) 5 (26%) 7 (37%)
*Propensity-matched aortic valve replacement (AVR) group (n  39). Data are presented as the number (%) of patients.
MTVG  mean transvalvular gradient.
Figure 3. Change in New York Heart Association (NYHA) functional
class symptoms in 44 of 46 late survivors in the aortic valve replacement
(AVR) group (p  0.001 for change in NYHA functional class III/IV
symptoms, preoperatively and postoperatively). N  number of patients.
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Possible mechanisms of perioperative survival. The peri-
operative survival among patients in the AVR group was
better than that of previously reported series (9,12). This
relates, in part, to the more recent period of our study, as
there have been advances in surgical techniques, improve-
ments in valve prostheses and related hemodynamic vari-
ables, anesthetic monitoring and the use of new inotropes,
such as phosphodiesterase inhibitors (34).
There was considerable improvement in valvular hemo-
dynamic data among those in-hospital survivors who re-
ceived postoperative echocardiography. The use of bovine-
pericardial tissue bioprostheses that have a low TVG,
especially with smaller sized prostheses (35,36), may have
contributed to this improvement in postoperative hemody-
namic data.
It is also possible the patients selected for AVR consisted
of a less sick cohort of patients, as compared with the
patients in other studies. At baseline in our study, the
prevalence of NYHA functional class III or IV symptoms
was 65%, compared with 85% reported in earlier series of
patients with severe AS and severe LV dysfunction (11,12).
This indicates that some patients were referred for surgery
owing to the presence of severe LV dysfunction, before
developing incapacitating symptoms. In addition, the im-
provement in late survival, as well as NYHA functional
class, of patients in the AVR group may have been partly
due to current advances in the medical management of
patients with LV dysfunction (37,38). We did not find a
mean TVG below which survival deteriorated; however,
as seen in Table 4, the number of patients with a TVG
25 mm Hg was too small to draw any conclusions.
Change in postoperative LVEF. Among patients with
severe AS, elevated TVG and LV dysfunction, AVR is
associated with improved postoperative LVEF (4,6,12,39).
This improvement reflects myocardial reserve, with the
relief of afterload mismatch.
After multiple linear regression analysis, the only predic-
tors of an increase in LVEF after AVR were the presence of
syncope and the absence of hypertension at baseline. Al-
though the occurrence of syncope is strongly associated with
severe AS, it had a low prevalence and was found only
among 8 (15%) of 53 patients. Structural remodeling of the
myocardium, with an abnormal accumulation of collagen
(40), can result in myocardial fibrosis (41) in patients with
hypertension. This may have contributed to persistent
myocardial dysfunction after the operation in those patients
in the AVR group who did not have improvement in
postoperative LVEF. Hypertension is also known to be a
risk factor for the development CAD; however, neither the
absence of CAD nor multivessel CAD predicted an im-
provement in postoperative LVEF in our study. Other
studies have found that AVA and female gender (6,42)
predicted increased postoperative LVEF.
Study limitations. This study was observational in design,
and not all the factors that influenced the decision to refer
or not to refer patients for surgery are known. It is likely that
the patients in the AVR group were expected to benefit
most, because of the presence of anatomically severe stenosis
and, likely, less severely detrimental comorbidities, as com-
pared with patients in the control group. Although we
undertook a detailed propensity analysis to correct for these
possible biases, it is possible there were factors not captured
among patients in the control group that affected survival.
This may have led to an overestimation of the benefit of
AVR surgery.
Dobutamine stress echocardiography aids in predicting
the benefit of AVR among this high-risk cohort with or
without CAD, by determining whether a fixed stenosis is
present (43). However, preoperative dobutamine stress
echocardiography was used in too few patients to assess its
predictive accuracy.
Conclusions. This study shows that among patients with
low TVG, severe AS and severe LV systolic dysfunction,
select patients who receive AVR are associated with signif-
icantly improved survival, as compared with those who did
not receive AVR. It also confirms previous reports (9,12)
demonstrating that survival is accompanied by an improve-
ment in functional status. Although these results are prom-
ising, they are still observational and derived from a small
number of patients. Thus, they can only be regarded as
hypothesis-generating. It will be important for them to be
reproduced among a large population of patients and in
other series, before AVR becomes an accepted treatment
strategy for this high-risk cohort.
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